PodParley PodParley
PodParley
Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025 episode artwork

EPISODE · Dec 2, 2025 · 6 MIN

Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025

from Medical Digest & Congress Report · host Medical Congress News

Professor Stephen Nicholls shares his insights on the pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial at AHA Scientific Sessions 2025.Video: https://medicaldigest.org/scientific-contents/interview:once-weekly-tirzepatide-versus-dulaglutide-heart-failure-outcomes-patients-type-2-diabetes-ascvd-and-history-heart-failure

Episode metadata supplied by the publisher feed · Published Dec 2, 2025

Embed this episode

Ready to play

Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025

0:00 6:52

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on December 2, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!